High-grade serous carcinoma (HGSC) is usually managed with a combination of surgery and platinum-based chemotherapy, followed by maintenance therapy with PARP inhibitors for patients diagnosed with HRD-associated tumours including BRCA1/2 pathogenic mutations [25]. This evidence concerns the gene BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome.